Janux Therapeutics, Inc.

NasdaqGM:JANX Rapport sur les actions

Capitalisation boursière : US$878.8m

Janux Therapeutics Gestion

Gestion contrôle des critères 2/4

Le PDG Janux Therapeutics est David Campbell, nommé en Jun2017, a un mandat de 8.92 ans. La rémunération annuelle totale est $ 13.51M, composée du salaire de 5% et des bonus 95%, y compris les actions et options de la société. détient directement 0.37% des actions de la société, d'une valeur de $ 3.23M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2 ans et 4.7 ans.

Informations clés

David Campbell

Directeur général

US$13.5m

Rémunération totale

Pourcentage du salaire du PDG5.03%
Durée du mandat du directeur général8.9yrs
Propriété du PDG0.4%
Durée moyenne d'occupation des postes de direction2yrs
Durée moyenne du mandat des membres du conseil d'administration4.7yrs

Mises à jour récentes de la gestion

Recent updates

Article d’analyse • May 13

Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts

Celebrations may be in order for Janux Therapeutics, Inc. ( NASDAQ:JANX ) shareholders, with the analysts delivering a...
Article d’analyse • May 11

Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Janux Therapeutics, Inc. ( NASDAQ:JANX ) came out with its quarterly results last week, and we wanted to see how the...
Seeking Alpha • May 04

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Summary Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial discipline, reallocating resources to higher-potential assets and further validating the TRACTr platform. Strategic partnerships with Merck and BMY could yield up to $1.8 billion in milestones plus royalties, supporting long-term value creation. Despite early-stage pipeline risks and near-term volatility, JANX’s cash position and platform progress justify a high-risk, long-term investment thesis. Read the full article on Seeking Alpha
Article d’analyse • Oct 08

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Article d’analyse • Apr 23

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Dec 03

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause

Summary Janux Therapeutics' TRACTr platform shows promise with encouraging early data, but the high valuation for a phase 1 company makes it a risky investment. The PSMA-targeted JANX007 has shown significant PSA reductions and partial tumor responses, but long-term efficacy and safety remain uncertain. JANX has a strong cash position, reducing immediate financial risks, but the market's high expectations could lead to severe valuation drops if data disappoints. Despite potential buyout rumors, the unproven nature of JANX's technology and the high market cap lead me to maintain a “Strong Sell” rating. Read the full article on Seeking Alpha
Article d’analyse • Oct 01

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 01

Janux Therapeutics: Buoyed By Buyout Speculation

Summary Today, we take another look at clinical stage biotech concern Janux Therapeutics, whose stock has soared in 2024. The shares have been buoyed throughout most of 2024 by a bevy of buyout speculation and some promising early-stage trial data. The company has a robust balance sheet and is targeting some potentially large markets. However, the company's pipeline is early-stage and there was some significant insider selling in the stock in early June at near all-time highs. Can the rally in Janux Therapeutics continue? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Article d’analyse • Jul 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 11

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Summary Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC treatment, with potential for dose optimization and safety balance. Amidst takeover speculation, Janux stock's valuation surged, yet I advise caution due to the speculative nature of acquisition outcomes. I recommend a cautious 'Buy' for JANX, highlighting its speculative nature, potential risks in drug development, and competition in the mCRPC market. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Summary Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. With positive single-agent activity of JANX007 observed in patients with metastatic castration-resistant prostate cancer, potential to advance combination therapy with PSMA targeting agent XTANDI. It is expected that the global prostate cancer therapeutics market could reach $28.5 billion by 2032. Positive preliminary data also observed for the other phase 1a study using JANX008 for the treatment of patients with EGFR expressing solid tumors. Read the full article on Seeking Alpha
Article d’analyse • Feb 24

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Article d’analyse • Dec 29

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Key Insights The projected fair value for Janux Therapeutics is US$18.66 based on 2 Stage Free Cash Flow to Equity...
Article d’analyse • Nov 04

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Article d’analyse • Jul 20

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Article d’analyse • May 23

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Key Insights The projected fair value for Janux Therapeutics is US$15.07 based on 2 Stage Free Cash Flow to Equity...
Article d’analyse • Feb 09

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d’analyse • Oct 19

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 09

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Janux Therapeutics press release (NASDAQ:JANX): Q2 GAAP EPS of -$0.41. Collaboration Revenue of $2.37M. The company had $354.3 million in cash and cash equivalents and short-term investments at end of second quarter 2022
Article d’analyse • Jun 05

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Article d’analyse • Feb 19

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Article d’analyse • Nov 03

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyse de la rémunération des PDG

Comment la rémunération de David Campbell a-t-elle évolué par rapport aux bénéfices de Janux Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Mar 31 2026n/an/a

-US$114m

Dec 31 2025US$14mUS$680k

-US$114m

Sep 30 2025n/an/a

-US$102m

Jun 30 2025n/an/a

-US$106m

Mar 31 2025n/an/a

-US$78m

Dec 31 2024US$9mUS$646k

-US$69m

Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$44m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$625k

-US$58m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$67m

Dec 31 2022US$6mUS$550k

-US$63m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$8mUS$459k

-US$33m

Sep 30 2021n/an/a

-US$21m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$812kUS$405k

-US$7m

Rémunération vs marché: La rémunération totale de David ($USD 13.51M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 3.71M ).

Rémunération et revenus: La rémunération de David a augmenté alors que l'entreprise n'est pas rentable.

PDG

David Campbell (65 yo)

8.9yrs
Titularisation
US$13,506,231
Compensation

Dr. David Campbell, Ph D serves as President, Chief Executive Officer Co-Founder and Director of Janux Therapeutics, Inc. since inception in June 2017. He founded Janux in 2017 to develop tumor-specific ca...

Équipe de direction

NomPositionTitularisationCompensationPropriété
David Campbell
President8.9yrsUS$13.51m0.37%
$ 3.2m
Thomas Diraimondo
Chief Scientific Officer2.3yrsUS$4.35m0.17%
$ 1.5m
Janeen Doyle
Chief Corporate & Business Development Officer1yrUS$4.67mpas de données
Matt Whitmire
Vice President of Finance1.8yrspas de donnéespas de données
Maria Dobek
Vice President of Accounting1.8yrspas de données0.0080%
$ 70.2k
Charles Winter
Chief Technical Officer3.3yrsUS$1.61m0.099%
$ 871.4k
James Pennington
General Counsel & Corporate Secretary4.8yrspas de donnéespas de données
William Go
Chief Medical Officerless than a yearpas de donnéespas de données
2.0yrs
Durée moyenne de l'emploi
48yo
Âge moyen

Gestion expérimentée: L'équipe de direction de JANX est considérée comme expérimentée (ancienneté moyenne 2 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
David Campbell
President8.9yrsUS$13.51m0.37%
$ 3.2m
Vickie Capps
Independent Director5.2yrsUS$389.22k0.12%
$ 1.0m
Ronald Barrett
Independent Chairperson4.7yrsUS$420.78k0.0041%
$ 36.0k
Eric Dobmeier
Independent Director1.8yrsUS$376.09k0.00020%
$ 1.8k
Mark Davis
Member of Scientific Advisory Boardno datapas de donnéespas de données
Alana McNulty
Independent Director4.7yrsUS$379.84k0.0041%
$ 36.0k
Julie Michele Cherrington
Member of Scientific Advisory Board1.1yrspas de donnéespas de données
Alessandra Cesano
Member of Scientific Advisory Boardless than a yearpas de donnéespas de données
Natasha Hernday
Independent Director1.8yrsUS$374.22k0%
$ 0
Sheila Gujrathi
Independent Director5.2yrsUS$370.47k0.19%
$ 1.7m
Winston Kung
Independent Director3.7yrsUS$379.84k0.0041%
$ 36.0k
Jake Simson
Independent Director5.2yrsUS$381.59k0%
$ 0
4.7yrs
Durée moyenne de l'emploi
62yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de JANX sont considérés comme expérimentés (ancienneté moyenne 4.7 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/22 06:13
Cours de l'action en fin de journée2026/05/22 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Janux Therapeutics, Inc. est couverte par 23 analystes. 14 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Etzer DaroutBarclays
Alec StranahanBofA Global Research
Suranjit MukherjeeBTIG